PSEN1 and Alzheimer disease: Some other data of Kummer et al. [52] have detected that the new PPAR agonist activates all PPARs receptors (GFT1803) decreases significantly Aβ plaques/Aβ level and microglia activation in AD mice (APP/PS1).